News Pregnant Women with Relapsing MS Can Use Copaxone Without Harming Baby, Study Indicates Pregnant Women with Relapsing MS Can Use Copaxone Without Harming Baby, Study Indicates by Joana Fernandes, PhD | May 8, 2017 Share this article: Share article via email Copy article link Babies of women with relapsing multiple sclerosis (RMS) who receive daily injections ofĀ Copaxone (glatiramer acetate) while pregnant carry the same risk of developing birth defects as babies as a whole, according to a study by the therapy’s developer,Ā Teva Pharmaceutical Industries. The findings can help doctors counsel and treat women with RMS who become pregnant.Ā The study,Ā āPregnancy Outcomes From The Branded Glatiramer Acetate Pregnancy Database,ā wasĀ published in the International Journal of MS Care. Copaxone is a synthetic protein that simulates the production of myelin, a substance that protects nerve fibers in the brain and spinal cord and that is degraded in MS. The drug also suppresses the immune system by preventing T-cells — a type of immune system cells — from damaging myelin in a process called demyelination. There have beenĀ no well-controlled studies in pregnant women’s use of Copaxone until now. Tevla decided to investigate whether babies born to MS patients treated with Copaxone while pregnant were at higher risk of having a congenital problem than babies as a whole. Researchers compared data on babies born to Copaxone-treated MS patients with data on babies born to healthy women. TheĀ 5,025 cases of Copaxone-treated women were in a database containing information on the therapy’s safety, known as the Glatiramer Acetate Pharmacovigilance Database. TheĀ two databases of healthy women were the the Metropolitan Atlanta Congenital Defects Program and the European Surveillance of Congenital Anomalies. Researchers’ analysis showed that the rates of congenital problems in the databases were comparable. This Ā indicated that there was no greater risk of a baby from a Copaxone-treated MS patients having a congenital problem than babies at large. āPhysicians now have this data to consider as they consult with their RMS patients planning a family or already pregnant, to make individual treatment decisions,ā Dr. Patricia K. Coyle, the studyās senior author, said in a news release. āWith more than 20 years of data collected on COPAXONE, we are able to share this important analysis with physicians to consider and counsel their patients of child-bearing age,ā added Dr. Rob Koremans, president and CEO of Teva Global Specialty Medicines. āWe are pleased to put forward this data that may help facilitate that conversation.ā Print This Page About the Author Joana Fernandes, PhD Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology. Tags Copaxone, Glatiramer acetate, pregnancy, Teva
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8